Boyang Sun

Dr. Boyang Sun


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 July 2016 in Advanced Materials
Verified
Journal Article
Open access
PDF file
YZYumiao Zhang
Yumiao Zhang
DWDepeng Wang
Depeng Wang
SGShreya Goel
Shreya Goel
BSBoyang Sun
Boyang Sun
Upendra ChitgupiUpendra Chitgupi
Upendra Chitgupi
Jonathan LovellJonathan Lovell
Jonathan Lovell
Edible, surfactant‐stripped, frozen micelles are formed from pheophytin (demetallated chlorophyll), a pigment that is naturally consumed in human diets. Pheophytin nanoparticles pass completely and safely through the gastrointestinal tract and enable trimodal gut contrast imaging via photoacoustic, fluorescence, and positron emission tomography techniques.

24 February 2025 in Cancer Biology & Medicine
Verified
Journal Article
Open access
PDF file
SCSiyuan Chen
Siyuan Chen
ZWZhijie Wang
Zhijie Wang
BSBoyang Sun
Boyang Sun

4 April 2023 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
BSBoyang Sun
Boyang Sun
TQTian Qiu
Tian Qiu
XZXiaoling Zeng
Xiaoling Zeng
JDJian Chun Duan
Jian Chun Duan
HBHua Bai
Hua Bai
ZWZhijie Wang
Zhijie Wang
Next-generation sequencing (NGS) has failed to detect mesenchymal epithelial transition factor gene (MET) polysomy in previous studies. We included three non–small cell lung cancer (NSCLC) cohorts in this retrospective study to establish new criteria for detecting MET polysomy and to explore the clinical relevance of MET polysomy. Cohort 1 included 53 patients whose tissues were available for both FISH and NGS assays. Paired plasma and tissue samples were obtained from 261 patients with NSCLC as cohort 2. Cohort 3 included 46 patients with metastatic NSCLC, who presented with MET copy-number gain assessed by NGS. ROC analysis demonstrated that a cut-off point of 2.3 copies achieved the maximum Youden index in discriminating polysomy from normal copy number. Compared with the FISH test for MET polysomy, the sensitivity, specificity, and agreement of NGS were 90%, 90%, and 96.2%, respectively. Following optimization using maximum somatic allele frequency, the sensitivity and specificity of NGS for defining polysomy using plasma samples according to different circulating tumor DNA mutation frequencies were 42% and 63%. The concordance rate between tissue and plasma samples for detecting polysomy was 85%. Regarding the response to MET inhibitor, the median progression-free survival (PFS) of the MET amplification group was significantly higher than that of the polysomy group. The median PFS was similar between the polysomy and normal groups. Our results indicated that NGS may serve as an alternative method for detecting MET polysomy in NSCLC tissues. Moreover, patients with MET polysomy may not benefit from MET inhibitors.Significance: In this study, we established a methodology to differentiate polysomy from normal copy numbers and amplification using NGS. Moreover, this study suggests that it is critical to discriminate MET polysomy from amplification, for the former may dilute the clinical benefit of MET inhibitors.

12 March 2022 in Translational Oncology
Verified
Journal Article
Open access
SGSanjana Ghosh
Sanjana Ghosh
BSBoyang Sun
Boyang Sun
DJDushyant Jahagirdar
Dushyant Jahagirdar
DLDandan Luo
Dandan Luo
JOJoaquin Ortega
Joaquin Ortega
Jonathan LovellJonathan Lovell
Jonathan Lovell
• A liposomal formulation of irinotecan that contains a non-exchangeable, embedded photosensitizer gives rise to enhanced serum stability and rapid light-triggered release when sucrosulfate is used as a trapping agent. • Pharmacokinetic and biodistribution studies reveal enhanced delivery of Irinotecan, active metabolite SN-38 and major metabolite SN-38 following tumor irradiation with red laser light, leading to ablation of MIA-PaCa2 tumors and low-passage pancreatic cancer patient-derived xenogratfs with a single treatment. • A pharmacokinetic model accounts for enhanced drug delivery based on photodynamic laser irradiation increasing tumor vascular permeability.

12 March 2026 in CA: A Cancer Journal for Clinicians
Verified
Journal Article
Open access
JDJian Chun Duan
Jian Chun Duan
JZJia Zhong
Jia Zhong
BSBoyang Sun
Boyang Sun
WZWen‐Hua Zhao
Wen‐Hua Zhao
LWLin Wu
Lin Wu
JWjie wang
jie wang
Third‐generation epidermal growth factor receptor–tyrosine kinase inhibitors (EGFR‐TKIs) are standard first‐line therapy for advanced, EGFR ‐mutated nonsmall cell lung cancer (NSCLC). However, their benefit is limited in patients who have co‐existing tumor suppressor gene (TSG) mutations, highlighting a need for intensified strategies to improve outcomes. ACROSS2 (ClinicalTrials.gov identifier NCT04500717) is the first prospective, multicenter, randomized phase 3 study to compare the third‐generation EGFR‐TKI aumolertinib in combination with carboplatin–pemetrexed versus aumolertinib monotherapy in patients who had NSCLC with EGFR mutations and concomitant TSG mutations. In total, 126 patients were enrolled and randomly assigned to either combination therapy ( n = 62) or monotherapy ( n = 64). The primary end point was median progression‐free survival (PFS). At a median follow‐up of 25.3 months, combination therapy significantly prolonged median PFS compared with monotherapy (19.78 vs 16.53 months; hazard ratio, 0.58; 95% confidence interval, 0.34–0.97). Landmark PFS rates at 12, 18, and 24 months were 78.7% versus 65.3%, 67.2% versus 40.8%, and 41.0% versus 29.9%, respectively. Subgroup analyses demonstrated a clear PFS benefit in patients who had co‐existing tumor protein p53 ( TP53 ) mutations. Grade 3 or greater adverse events occurred in 25.9% of patients who received combination therapy versus 17.2% of those who received monotherapy; no drug‐related deaths were observed. Overall survival data were immature (data maturity, 4%). The ACROSS2 trial provides the first prospective evidence supporting a genotype‐directed, chemotherapy‐targeted intensification approach favoring aumolertinib plus carboplatin–pemetrexed for this molecularly defined population.

12 March 2020 in Advanced Therapeutics
Verified
Journal Article
Open access
PDF file
BSBoyang Sun
Boyang Sun
Upendra ChitgupiUpendra Chitgupi
Upendra Chitgupi
CLChangning Li
Changning Li
JFJasmin Federizon
Jasmin Federizon
CZChangjie Zhang
Changjie Zhang
Jonathan LovellJonathan Lovell
Jonathan Lovell
The cover image representing article number 1900161 by Jonathan F Lovell and co‐workers shows aggregates formed by the anti‐cancer drug cabazitaxel. In this work, it is shown that by co‐formulating cabazitaxel in unique surfactant micelles with certain other hydrophobic cargo, aggregation can be prevented, resulting in a potent chemotherapy formulation with long‐term liquid storage stability and a high drug‐to‐excipient ratio.